Everhart Financial Group Inc. Acquires Shares of 1,322 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Everhart Financial Group Inc. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 1,322 shares of the biopharmaceutical company’s stock, valued at approximately $321,000.

Other large investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Altitude Crest Partners Inc. purchased a new stake in Alnylam Pharmaceuticals in the first quarter worth about $30,000. GAMMA Investing LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $52,000. V Square Quantitative Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $52,000. Finally, Lindbrook Capital LLC boosted its position in shares of Alnylam Pharmaceuticals by 37.2% in the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. SVB Leerink raised their price objective on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research note on Tuesday, June 25th. Barclays increased their price target on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 29th. Finally, Raymond James upped their price objective on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $277.14.

Alnylam Pharmaceuticals Trading Down 1.7 %

Shares of ALNY traded down $4.69 during trading hours on Friday, reaching $272.64. 359,258 shares of the stock traded hands, compared to its average volume of 881,397. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $285.00. The company has a market cap of $34.49 billion, a P/E ratio of -101.73 and a beta of 0.37. The company’s 50-day moving average price is $244.13 and its two-hundred day moving average price is $183.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The business’s revenue was up 107.0% on a year-over-year basis. During the same period last year, the company earned ($2.21) EPS. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the transaction, the executive vice president now owns 14,181 shares in the company, valued at $3,275,669.19. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the sale, the executive vice president now directly owns 14,181 shares in the company, valued at $3,275,669.19. The disclosure for this sale can be found here. Insiders sold a total of 124,848 shares of company stock valued at $28,883,444 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.